EGM
CLDX icon

Engineers Gate Manager’s Celldex Therapeutics CLDX Stock Holding History

Engineers Gate Manager’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Buy
+33,842
New +$1.09M 0.02% 945
2025
Q2 		– Sell
-15,402
Closed -$280K – 2203
2025
Q1 		$280K Buy
15,402
+3,913
+34% +$87.4K ﹤0.01% 1747
2024
Q4 		$290K Sell
11,489
-26,997
-70% -$733K 0.01% 1714
2024
Q3 		$1.31M Buy
38,486
+30,732
+396% +$1.17M 0.03% 848
2024
Q2 		$287K Sell
7,754
-18,852
-71% -$711K 0.01% 1496
2024
Q1 		$1.12M Buy
26,606
+17,536
+193% +$720K 0.03% 763
2023
Q4 		$360K Sell
9,070
-4,583
-34% -$135K 0.01% 1351
2023
Q3 		$376K Buy
+13,653
New +$428K 0.01% 1211
2023
Q2 		– Sell
-8,227
Closed -$296K – 1767
2023
Q1 		$296K Buy
+8,227
New +$355K 0.01% 1244
2022
Q4 		– Sell
-12,317
Closed -$346K – 1714
2022
Q3 		$346K Buy
+12,317
New +$378K 0.02% 1031
2022
Q2 		– Sell
-7,086
Closed -$241K – 1951
2022
Q1 		$241K Buy
+7,086
New +$227K 0.01% 1536
2016
Q1 		– Sell
-735
Closed -$173K – 691
2015
Q4 		$173K Buy
+735
New +$160K 0.01% 612

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Engineers Gate Manager's CLDX Position: Q2 2026 in Review

Engineers Gate Manager opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 33,842 shares worth $1.26M. The stake represents 0.02% of the portfolio and ranks #945 among its holdings. This is a return to the name: Engineers Gate Manager previously reported a position in CLDX as recently as Q1 2025.

Engineers Gate Manager first reported a position in CLDX in Q4 2015 and has held it in 12 quarters since. The position peaked at $1.31M in Q3 2024. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Engineers Gate Manager held 33,842 shares of Celldex Therapeutics worth $1.26M as of Q2 2026.
  • Celldex Therapeutics was a new Engineers Gate Manager position in Q2 2026.
  • Celldex Therapeutics made up 0.02% of Engineers Gate Manager's portfolio in Q2 2026, its #945 holding.
  • Engineers Gate Manager first reported a position in Celldex Therapeutics in Q4 2015 and has held it in 12 quarters since.
  • Engineers Gate Manager's Celldex Therapeutics position peaked at $1.31M in Q3 2024.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.